Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
http://www.breast-cancer-research.co...df/bcr2944.pdf
[2011, Breast Cancer Research] -- this predates Herceptin and Perjeta but the protein links is very interesting and might help with tissue genetic profiling.
" Luminal A cancers had a propensity to give rise first to bone
metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1, those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5) and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and
infrequently ER and PgR."
Breast cancer molecular subtype: HER2+/HR-
No. of patients: 36
No. of metastatic sites: 48
Bone: 14 (29.2)
Liver: 13 (27.1)
Lung: 11 (22.9)
Non-regional lymph nodes: 4 (8.3)
Skin: 4 (8.3)
Pleura: 0 (0.0)
Brain: 1 (2.1)
Other 1 (2.1